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Abstract 
Background: Intra‑abdominal surgical intervention can cause the development of intra‑peritoneal adhesions. To 
reduce this problem, different agents have been tested to minimize abdominal adhesions; however, the optimal 
adhesion prophylaxis has not been found so far. Therefore, the A‑Part® Gel was developed as a barrier to diminish 
postsurgical adhesions; the aim of this randomized controlled study was a first evaluation of its safety and efficacy.
Methods: In this prospective, controlled, randomized, patient‑blinded, monocenter phase I–II study, 62 patients 
received either the hydrogel A‑Part‑Gel® as an anti‑adhesive barrier or were untreated after primary elective median 
laparotomy. Primary endpoint was the occurrence of peritonitis and/or wound healing impairment 28 ± 10 days 
postoperatively. As secondary endpoints anastomotic leakage until 28 days after surgery, adverse events and adhe‑
sions were assessed until 3 months postoperatively.
Results: A lower rate of wound healing impairment and/or peritonitis was observed in the A‑Part Gel® group 
compared to the control group: (6.5 vs. 13.8 %). The difference between the two groups was −7.3%, 90 % confidence 
interval [−20.1, 5.4 %]. Both treatment groups showed similar frequency of anastomotic leakage but incidence of 
adverse events and serious adverse events were slightly lower in the A‑Part Gel® group compared to the control. 
Adhesion rates were comparable in both groups.
Conclusion: A‑Part Gel® is safe as an adhesion prophylaxis after abdominal wall surgery but no reduction of postop‑
erative peritoneal adhesion could be found in comparison to the control group. This may at least in part be due to the 
small sample size as well as to the incomplete coverage of the incision due to the used application.
Trial Registration: NCT00646412
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Background
Rationale
Postoperative adhesions occur when fibrous strands of 
internal scars attach to anatomical structures. Previ-
ous intra-abdominal surgical interventions are a com-
mon cause of peritoneal adhesions [1–3]. The most 
severe complications based on the occurrence of 
intra-abdominal adhesions are small bowel obstruction 
(60–70 %), female infertility (20–40 %), chronic abdomi-
nal pain and technical difficulties in the case of a reop-
eration [3]. A variety of adhesion barriers and strategies 
have been developed in order to prevent or at least to 
reduce postoperative adhesions [1, 4]. These include 
films, viscous gels or intra-abdominal solutions, but so 
far no standard treatment has been established [1, 4]. The 
most common method in adhesion prevention is to apply 
a barrier between the wounded surfaces. Barrier materi-
als should be easy to apply and should remain in place for 
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several days to allow serosal re-epithelium formation and 
should be absorbed afterwards and excreted without sys-
temic reactions or inappropriate accumulation. Materials 
that are non-inflammatory, non-reactive and not inter-
fering with the healing process of incision wounds or 
anastomoses are well suitable. Until today, the problem of 
peritoneal adhesions remains in general largely unsolved 
and an effective prevention method is not routinely used 
in abdominal surgery leading to significant clinical and 
economical consequences [5]. Annual costs of peritoneal 
adhesion related problems are estimated in Sweden to 
be €40–60 million; and more than 300,000 patients are 
estimated to undergo treatment due to adhesion induced 
small bowel obstruction in the US annually [6, 7].
Thus, the hydrogel A-Part Gel® which is a bio-absorb-
able transparent gel composed of polyvinylalcohol (PVA) 
and carboxymethylcellulose (CMC) was developed. Both 
components are used for various biomedical applica-
tions and their biocompatibility have been confirmed [8]. 
A-Part Gel® is intended to operate as a physical barrier 
between injured surface to reduce post-surgical adhe-
sions [9, 10].
Purpose
A variety of experimental studies in different animal 
models have been conducted which showed that A-Part 
Gel® is efficacious in the reduction of post-surgical adhe-
sions in vivo [11–16]. Therefore, the aim of this study was 
clearly the evaluation of the safety and secondly an esti-
mation of the efficacy of this hydrogel in the peritoneal 
adhesions prevention after primary elective laparotomy 
compared to an untreated control group in humans.
Methods
To demonstrate transparency, the study protocol of the 
trial has already been registered (http://www.clinical-
trials.gov) and published [17]. The study is approved by 
the ethics committee of the Ludwig-Maximilians Uni-
versity (LMU), Munich, Germany. It was sponsored and 
conducted by Aesculap AG, Tuttlingen, Germany. The 
sponsor has taken out an insurance policy to cover all 
patients participating in the trial. The Clinical Trials Unit 
of the University Medical Center Freiburg, Germany, was 
responsible for project management, database mainte-
nance, biometrics and data analysis. Monitoring was 
performed by authorized and qualified persons of Lab-
Consult, Freiburg Germany. Patients were enrolled at one 
center in Germany (The Department of Surgery, Univer-
sity of Munich Großhadern, Munich, Germany).
Trial design
This study was conducted as a prospective, controlled, 
randomized, patient- and observer-blinded, monocenter 
phase I–II study. Patients were intra-operatively ran-
domly allocated to the treatment group receiving A-Part-
Gel® before the closure of the abdominal wall or to the 
untreated control group (parallel, ratio 1:1). Due to safety 
aspects a staggering of the treatment of the patients was 
performed at the beginning of the study. The first 20 ran-
domized patients were subsequently included into the 
study, so that a time interval of at least 96  h had to be 
kept between the treatments of the first 10 patients, and 
a time interval of at least 48  h had to be kept between 
the treatments of the next 10 patients. In each group 31 
patients were included and after discharge from the hos-
pital the patients were examined after 28 (±10) days and 
after 3 months (±14 days) postoperatively [17]. The study 
design has not been changed, the study was performed as 
described in the published study protocol [17].
Participants
Inclusion and exclusion criteria were described previ-
ously [17]. Patients undergoing an elective median pri-
mary laparotomy with an expected incision length of 
≥15  cm were eligible and were asked for their written 
informed consent after they had been informed about the 
purpose of the trial, the surgical modalities, data manage-
ment and their benefits and risks. Patients with a previ-
ous median laparotomy and any other abdominal surgery 
were not included into the study (exceptions: previous 
laparoscopic appendectomy, cholecystectomy, inguinal 
hernia repair, gynecological tube sterilization).
Interventions
The closure of the abdominal wall was standardized. 
In each randomized patient the abdominal fascia was 
closed from the caudal and cranial end using a long-
term absorbable monofilament suture loop in accord-
ance to the continuous suture technique published in 
the INSECT Trial [18]. In the control group the incision 
was closed without the application of the prophylactic 
gel. In case of the treatment group up to 3 cm of the inci-
sion was left open in the middle. A-Part Gel® was applied 
without sight under the incision through the remain-
ing opening of the fascia. The gel syringe was placed 
intra-abdominally to one end of the incision and blindly 
applied along the partly sutured incision while pressing 
out slowly the prophylactic gel. The same procedure was 
used for the other half of the sutured incision. Thereafter, 
the syringe was taken out from the incision and the clo-
sure of the abdominal wall was completed. Skin closure 
was performed by skin staples. It was recommended to 
use 1 ml of the prophylactic gel to cover 1 cm of the inci-
sion. Participating surgeons performing the intervention 
were instructed by detailed manuals and only trained 
surgeons applied the adhesion prophylaxis.
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Study device
A-Part Gel® consists of two unmodified water soluble 
biocompatible polymers: polyvinyl alcohol (PVA) and 
CMC, mixture 25:1 [8, 9]. PVA is biologically inert and 
is not degraded in mammal metabolism. As a water solu-
ble polymer, PVA is mainly excreted by the kidneys, only 
small amounts are excreted via faeces. CMC is a cellulose 
derivative which is already widely used in pharmaceuti-
cal, nutritional and cosmetic products. CMC is classi-
fied in the group “substances that are generally regarded 
as safe”. Cellulose derivative like CMC are already used 
as barrier materials for adhesion protection with good 
results regarding efficacy and biocompatibility. To pre-
pare A-Part Gel® both substrates PVA and CMC are 
cross-linked by freeze-thawing cycles. PVA is the antiad-
hesion component while CMC promotes attachment to 
the wound site. The viscous gel is elastic, soft, translucent 
and absorbable [9]. The gel operates as a physical barrier 
between injured peritoneal surfaces to prevent post oper-
ative adhesions. It is absorbed in approximately 6 weeks 
and excreted via the kidneys [19]. For this clinical study 
the gel was filled in syringes (10  ml) steam-sterilized. 
Physical properties such as viscosity and adherence to the 
wound have been tested with good results [8, 9]. In ani-
mal studies it has been shown that A-Part Gel® operates 
as a physical barrier between injured peritoneal surfaces 
to prevent surgical postoperative adhesions in  vivo [9, 
11–16].
Outcomes
The primary objective of this study was a first assess-
ment of the safety of A-Part Gel® applied as an adhe-
sion prophylaxis after major abdominal surgery. The 
primary endpoint was the specific observation of two 
major complications of abdominal surgery: wound heal-
ing impairment and/or peritonitis within 28  ±  10  days 
after surgery compared to an untreated control group. 
Patients were defined as experiencing this event, if one 
or more of the single events occurred within the first 
28 ±  10  days postoperatively. The events were assessed 
at day 1, 4, 7 after surgery, at day of discharge and at day 
28. In case of missing assessments, patients were defined 
as not experiencing the endpoint, if it had not been diag-
nosed at the complete assessments. As a sensitivity anal-
ysis, patients with at least one missing assessment or at 
least one assessment outside the requested time frame 
were excluded from the analysis. Impaired wound heal-
ing was defined as delayed wound healing (necrosis or 
dehiscence) or as the development of a surgical infec-
tion; further details and the definition of a peritonitis are 
described in the protocol publication [17].
Post-operative peritonitis was diagnosed according to 
the following criteria: Post-operative peritonitis must be 
always suspected if fever, leukocytosis, abdominal pain, 
muscular defence, absence of bowel sounds, metabolic 
disturbance or severe hypotension with multiple organ 
failure occur. At least one of the following diagnostic pro-
cedures must be used to confirm the suspected diagnosis:




Impaired wound healing was defined as:
A. Delayed wound healing: delayed wound healing has 
to be diagnosed if at least one of the following criteria 
is fulfilled:
(a) Necroses of wound edges occur or if
(b) Primary or secondary dehiscence occurs (pri-
mary dehiscence is defined as retreating of 
wound edges immediately after surgery; second-
ary dehiscence is defined as retreating of wound 
edges after start of the wound healing).
B. Development of surgical site infection: surgical site 
infection has to be assumed as present, if one of the 
following criteria is fulfilled:
(a) Purulent secretion from the wound.
(b) Germ organism isolated from an aseptic 
obtained culture of fluid or tissue from superfi-
cial incision.
(c) Local signs of infection and/or systemic signs 
(e.g. fever, leukocytosis, rising CRP without 
other plausible causes (e.g. pneumonia, urinary 
tract infection).
(d) Diagnosis of an abscess in deep soft tissue (an 
abscess in deep soft tissue is defined as microbi-
ological verification of suspect specimen which 
is generally taken by means of ultra puncture).
Secondary endpoints to evaluate the safety were the 
(a) incidence of anastomotic leakage until 28 ±  10 days 
postoperatively, (b) adverse events (AE) and serious 
adverse events (SAE) occurring from the day of surgery 
until 3 months after operation and (c) laboratory assess-
ments. All AEs were coded using the Medical Diction-
ary for Regulatory Activities (MedDRA, Version 13.0). 
Laboratory tests included blood counts, including WBC, 
electrolytes, creatinine, urea, ASAT (GOT), ALAT 
(GPT), y-GT, total bilirubin, LDH, albumin and CRP. 
Laboratory tests were done before surgery, 1, 2, 4, 7 days 
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postoperatively, at discharge, 28 ± 10 days and 3 months 
after surgery, respectively. These tests were performed in 
the local laboratory of the clinical site.
Additionally the peritoneal adhesions in percent 
along the scar, resulting from blinded ultrasonographic 
examinations at 14 (range 7–14) days after surgery, as 
well as 28 ± 10 days and 3 months postoperatively were 
determined.
Sigel et  al. [20] described a method for non-invasive 
ultrasound examination to detect and to map abdominal 
adhesions. Using this technique peritoneal adhesions are 
identified by the presence or restrictions of the ultrasoni-
cally observed movement of the abdominal viscera in ref-
erence to the abdominal wall. A sensitivity of over 90 % 
and a specificity between 86 and 93 % have been reported 
for this technique in different studies [21–23]. To assess 
the incidence of postoperative abdominal adhesions the 
method of Sigel et  al. [20] was employed using a linear 
array transducer. Here, the scar of the abdominal incision 
was divided into equal parts of 2.5 cm, starting 2 cm from 
the cranial entrée of the scar. At each assessment point 
spontaneous visceral sliding was examined using ultra-
sound scanning. Sliding is the result of force applied by 
respiratory excursions or by manual ballottement of the 
abdominal wall and is referred to as viscera slide. In the 
case of reduced movement following respiration this was 
counted as a restricted visceral slide, i.e. adhesion. The 
documentation for each patient included the total assess-
ment points as well as the number of assessment points 
with adhesions. Ultrasound assessment was done by a 
blinded clinician. Furthermore, a video of the ultrasound 
examination was prepared by the investigator and evalu-
ated in addition by an external reviewer.
Sample size
This trial was conducted as a phase I–II study with the 
goal to generate the first safety data for the A-Part Gel® 
in human beings compared to the control group. Sam-
ple size considerations were not based on statistical cal-
culations, but more on feasibility of recruitment. It was 
planned to randomize a total of 60 patients between 
both treatment arms because it was expected that this 
patient number could be recruited by one center within 
6  months. The power considerations were based on the 
primary endpoint “occurrence of wound healing impair-
ment and/or peritonitis within 28  ±  10  days after sur-
gery”. It was assumed that without the application of the 
prophylactic gel wound healing impairment will occur 
with a probability of about 5–10  % and postoperative 
peritonitis with a probability of 2–5 % [23–25]. Therefore, 
it has been assumed that the primary endpoint will occur 
in the control group with a probability of about 7–15 %. 
Under the assumption that application of A-Part Gel® 
will not increase this probability, this study can show at 
one-sided significance level α = 0.05 with a power of 80 % 
that the difference of the event probabilities between the 
two treatment groups is not larger than 20–25 % [26].
Randomisation
To provide treatment groups of approximately equal 
sizes, block randomization with randomly varying block 
sizes and a ratio of 1:1 were used. To guarantee conceal-
ment of the randomization, the clinical investigator was 
unaware of the block length and the randomization list 
was generated and stored by the Clinical Trials Unit of 
the University Medical Center Freiburg, Germany. Num-
bered sealed opaque envelops prepared by the Clini-
cal Trials Unit were used for randomization which took 
place intra-operatively before closing the abdominal wall. 
Patients were enrolled and assigned to the treatment 
groups by the clinical investigator.
Blinding
Both patients and observers who performed the ultra-
sound examination and the video assessment were 
blinded in this study. None of the patients received any 
information about the allocation to the different treat-
ment groups (single-blinded). In addition, the observer 
had no access to the randomization result, which was 
not visible in the patient file and case report form (CRF). 
Blinding of the surgeon was not possible, because no 
matching placebo was available. Emergency envel-
ops were produced for unblinding if needed during the 
follow-up of the patients. In the case of an accidental 
unblinding of the examiner or the patient this was docu-
mented in the CRF and notified to the study coordinator.
Statistical methods
The statistical methods for analysis were described in 
the statistical analysis plan (SAP). All analyses were per-
formed using the Statistical Analysis System (SAS) ver-
sion 9.2. No interim analysis was planned and conducted 
in this study.
Analyses of safety endpoints were performed in the 
safety population, and analyses of efficacy endpoints 
were performed in the intention-to-treat (ITT) popula-
tion. It was preplanned in the study protocol to include 
all randomised patients in both analysis populations. As 
it happened during study conduct, that the randomisa-
tion envelope was opened before the exclusion criteria 
are fulfilled, patients will be excluded from the SAF set, 
if an exclusion criterion to be checked during surgery or 
the planned surgery is violated. Group assignment in the 
safety population is by treatment received, i.e. patients 
are counted to the A-Part group if they receive the 
A-Part® Gel, otherwise they are counted to the control 
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group. Group assignment in the ITT population is strictly 
by randomisation; even if A Part® Gel cannot be applied 
because of technical reasons, the patient is recorded in 
the A-Part group.
The aim of the study was to show that the application 
of A-Part Gel® will not lead to an unacceptable increase 
in the probability of occurrence of the primary endpoint 
“occurrence of wound healing impairment and/or peri-
tonitis within 28  ±  10  days after surgery”, i.e. the non-
inferiority of A-Part Gel® as compared to control. For 
this first safety study, the non-inferiority margin was set 
to 0.25. The two-sided 90 %-confidence interval (CI) for 
the absolute difference (A-Part® Gel minus control) of 
probability of occurrence of the primary endpoint will 
be calculated. If the upper bound of this CI is below 0.25, 
the hypothesis that the difference is 0.25 or larger will be 
rejected.
Rates of the secondary safety endpoints wound healing 
impairment, postoperative peritonitis, delayed wound 
healing, surgical site infection, anastomotic leakage, and 
AE were calculated with two-sided 90  % CIs. AEs were 
summarized by MedDRA preferred terms and by system 
organ classes.
For a first efficacy assessment of A-Part® Gel as com-
pared to the control the adhesion rates along the scar 
were calculated per patient 14  days (range 7–14  days), 
28 (+10) days and 3 months (±14 days) after surgery as 
the number of assessment points with adhesions divided 
by the total number of assessment points. The arith-
metic mean of the adhesion rates were calculated with 
two-sided 90  % CI. Additionally, the rate of patients 
experiencing an adhesion, i.e. patients with at least one 
assessment point with adhesion, were be calculated 
with two-sided 90  % CI. A separate analysis has been 
conducted for ultrasound assessment done by the clini-
cian and for video assessment performed by an external 
reviewer 3 months after surgery.
Quality assurance
The study was monitored by LabConsult GmbH. On-site 
visits were performed before study initiation and on a 
regular basis during the study. The monitor was respon-
sible for reviewing the progress of the ongoing study with 
the investigator in order to verify adherence to the study 
protocol. The investigator assisted the monitor in resolv-
ing any problems detected during monitoring visits.
Data entry, data management, data checks as well as 
query generation and resolution were done using the 
validated data management system DAMAST (V03-1) 
based on the program Statistical Analysis System (SAS) 
version 9.2. Double data entry was performed by two dif-
ferent persons. Computerized and visual methods of data 
verification were conducted to obtain complete, correct 
and plausible data for subsequent statistical analysis. A 
data management audit for the data management system 
DAMAST was performed in April 2010 at the Clinical 
Trials Unit in Freiburg. The Clinical Trials Unit was also 
certified according to ISO 9001:2008 in June 2009.
Results
Participants flow
In total 64 patients were asked to participate. Of those 62 
patients agreed and were randomized between July 2008 
and December 2009 (Fig.  1). Two randomized patients 
were excluded from the analysis populations because 
they violated intra-operatively the exclusion criterion 
“Peritoneal carcinosis” and therefore, the indicated sur-
gery was consequently not performed. Thus, a total of 
60 patients were included in the ITT population (in each 
treatment group 30 patients) and in the safety population 
(31 patients in the A-Part Gel® group and 29 patients in 
the control group); one patient randomized to the control 
group received A-Part-Gel® (Fig. 1). For 14 patients in the 
A-Part Gel® group and 15 patients in the control group, 
all investigations for the assessment of the safety end-
points were complete and at the requested time points. 
Three patients in the A-Part group and four patients in 
the control group had one or more missing assessment. 
In the A-Part group, these patients had their last assess-
ment on day 4, 9, and 14, in the control group, these 
patients had their last assessment on day 1, 4, 20, and 26. 
All other patients classified as not having all assessments 
complete an in time, had their 28 day visit later than day 
38 (day 39 to day 98) and were assessed at this visit as not 
having experienced the respective events.
Baseline data
A-Part Gel® treatment group and the control group were 
comparable with respect to age, gender, ethnic origin, 
nicotine and alcohol consumption, BMI and ASA status 
(Table 1). Regarding past medical history the number of 
patients with at least one disorder was similar in both 
groups (93.3  %, respectively). Frequency of diseases by 
organ system showed that cardiovascular, endocrino-
logic, neurologic and other diseases were less frequent 
in the A-Part Gel® group compared with the control 
group (data not shown). Types of surgeries are shown 
in Table  2. A small imbalance regarding the quantity of 
bowel anastomoses was observed. The number of bowel 
anastomoses was slightly higher in the control group 
compared to the A-Part Gel group. Number of anasto-
mosis are reported in Table 1.
Surgical intervention
Surgical procedure characteristics such as length of inci-
sion, surgical wound classification, skin closing method, 
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estimated blood loss, duration of surgery and ome-
netomy were comparable (data not shown). None of the 
patients received peri-operative steroids, whereas peri-
operative antibiotics were administered to all patients 
with except one patient in the A-Part Gel® group. A small 
imbalance was seen regarding the quantity of bowel anas-
tomoses. The number of bowel anastomoses was slightly 
higher in the control group than in the A-Part Gel® 
group (Table  1). The mean amount of gel applied was 
20 ml (min. 10 ml; max. 20 ml). Two syringes of hydrogel 
per patient were used in all 31 patients.
Outcomes
Wound healing impairment and/or postoperative peritonitis
A lower rate of wound healing impairment and/or peri-
tonitis within 28 ± 10 days postoperatively was observed 
in the A-Part Gel® group compared to the control group: 
(0.065, 90 % CI [0.012, 0.189] vs. 0.138, 90 % CI [0.049, 
0.288]; respectively) (Table  3). The difference between 
the two groups was −0.073, 90  % CI [−0.201, 0.054]; 
therefore, the upper bound of the 90  % CI interval was 
lower than the non-inferiority margin of 0.25 which indi-
cated that A-Part Gel® treatment was not inferior to the 
untreated control group in this respect. As a sensitivity 
analysis, patients with at least one missing assessment or 
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Fig. 1 CONSORT diagram
Table 1 Demography and medical history
*Missing: N = 16 (A-Part Gel: N = 7, Control: N = 9)
A-Part-Gel (N = 30) Control (N = 30)
Age; mean (yr) 60.8 64.0
Gender
Male 18 (60 %) 22 (73.3 %)
Female 12 (40 %) 8 (26.7 %)
Smoking status
Never 20 (66.7 %) 17 (56.7 %)
Stopped 7 (23.3 %) 10 (33.3 %)
Still 3 (10.0 %) 3 (10.0 %)
Alcohol consumption; mean  
(g/die)*
6 4
BMI [kg/m2] 25.68 26.63
ASA Classification
1 7 (23.3 %) 6 (20.0 %)
2 16 (53.3 %) 16 (53.3 %)
3 6 (20.0 %) 8 (26.7 %)
4 1 (3.3 %) 0 (0.0 %)
Number of bowel anastomoses
0 8 (26.7 %) 4 (13.3 %)
1 16 (53.3 %) 13 (43.3 %)
2 3 (10.0 %) 7 (23.3 %)
3 3 (10.0 %) 5 (16.7 %)
4 0 (0.0 %) 1 (3.3 %)
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were excluded from the analysis. This resulted in a differ-
ence between the two groups of −0.124, 90 % CI [−0.367, 
0.119].
In addition, both groups were analysed with respect to 
the incidence of the single endpoints forming the com-
posed primary endpoint, namely delayed wound heal-
ing, postoperative peritonitis, surgical site infection and 
wound healing impairment (Table  3). Consideration of 
these single safety endpoints showed that the rates of 
both groups were similar.
Anastomotic leakage
The rate of anastomosis leakage within 28 days after sur-
gery in the A-Part® Gel group as compared to the control 
group was 0.097, 90 % CI [0.027, 0.232] vs. 0.103, 90 % CI 
[0.029, 0.246] respectively (three out of 31 vs. three out of 
29 patients). So, the A-Part® Gel group and the control 
group were similar regarding the relative frequencies of 
anastomosis leakage (Table 3).
Adverse and serious adverse events
The number of adverse events (AE) was lower in the 
A-Part Gel® group than in the control group (44 vs. 60); 
however the number of patients with at least one AE 
were comparable in both groups (61.3 vs. 72.4  %). The 
most frequently reported adverse events for the A-Part 
Gel® and the control belonged to the following system 
organ classes: infections and infestations (9.7 vs. 34.5 %), 
gastrointestinal disorders (16.1 vs. 20.7 %), injury poison-
ing and procedural complications (12.9 vs. 20.7  %) and 
general disorders and administration site conditions (9.7 
vs. 17.2 %).
A slight lower rate of patients having at least one SAE 
were observed in the A-Part Gel® group (29.0 %) as com-
pared to the control group (41.4  %); whereas the total 
number of SAEs were similar in both groups (A-Part 
Gel®; n  =  20 vs. control; n  =  23). In both groups, the 
most frequently reported SAEs were in the following 
system organ classes: Gastrointestinal disorders (3.2 
vs. 13.8  %), infections and infestations (3.2 vs. 13.8  %), 
cardiac disorders (6.5 vs. 3.4  %), general disorders and 
administration site conditions (6.5 vs. 3.4  %) and injury 
poisoning and procedural complications (12.9 vs. 13.8 %), 
A-Part Gel® group vs. control group, respectively.
Two patients died in each treatment group during the 
study. One patient in the A-Part Gel® group deceased 
because of a septic shock one month after surgery and 
the other patient due to a multiple organ failure four 
months postoperatively. These SAEs were documented in 
the first case as unrelated to the medical device and in the 
second case as unlikely, because after 1 and 4 months the 
A-Part Gel® has been absorbed. In the control group two 
patients had a fatal outcome because of a septic shock 
one day after surgery, and for the second patient anaphy-
laxia was recorded one day postoperatively. No patient 
Table 2 Types of surgeries
AAA Abdominal aortic aneurysm
A-Part-Gel (N = 31) Control (N = 29)
Rectal cancer 6 (19 %) 3 (10 %)
Gastric cancer 6 (19 %) 6 (21 %)
Colon cancer 7 (23 %) 3 (10 %)
Pancreatic cancer 4 (13 %) 10 (34 %)
Esophagus Cancer 1 (3 %) 2 (7 %)
Sigma diverticulitis 1 (3 %) 2 (7 %)
Infrarenal AAA 2 (6 %) 0 (0 %)
Spleen tumor 1 (3 %) 0 (0 %)
Soft tissue tumor 0 (0 %) 1 (3 %)
Hernia 0 (0 %) 0 (0 %)
Others 3 (10 %) 2 (7 %)
Table 3 Primary endpoint: safety
A-Part-Gel (N = 31) Control (N = 29)
Wound healing impairment and /or peritonitis 2 (6.5 %) 4 (13.8 %)
90% CI [0.012, 0.189] 90 % CI [0.049, 0.288]
Peritonitis 1 (3.2 %) 0 (0.0 %)
90 % CI [0.002, 0.144] 90 % CI [0.000, 0.098]
Delayed wound healing 2 (6.5 %) 4 (13.8 %)
90 % CI [0.012, 0.189] 90 % CI [0.049, 0.288]
Surgical site infection 1 (3.2 %) 3 (10.3 %)
90 % CI [0.002, 0.144] 90 % CI [0.029, 0.249]
Impaired wound healing 2 (6.5 %) 4 (13.8 %)
90 % CI [0.012, 0.189] 90 % CI [0.049, 0.288]
Anastomotic leakage 3 (9.7 %) 3 (10.3 %)
90 % CI [0.027, 0.232] 90 % CI [0.029, 0.246]
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was withdrawn from the study due to an adverse event. 
Analysis of the laboratory data revealed no differences 
between the two treatment groups (data not shown).
Postoperative adhesions
Total number of assessment points for determination 
of adhesions was comparable in the A-Part Gel® group 
and control group at all time-points (data not shown). 
No clear difference was seen between the A-Part Gel® 
patients and untreated patients in respect to adhesion 
rates along the scar and patients experiencing an adhe-
sion (Table  4). The results indicated that both groups 
were comparable and a reduction of postoperative peri-
toneal adhesions could not be found in the A-Part Gel® 
group in this study.
Discussion
Adhesions between visceral organs and the abdominal 
wall remain a major challenge in abdominal and pelvic 
surgery leading to major long-term complications such as 
small and large bowel obstruction, pain, and female infer-
tility [2, 3, 5, 27–29]. Patients undergoing lower abdomi-
nal surgery are reported to have a 5 % risk of readmission 
directly related to adhesions within 5 years following sur-
gery [27]. To reduce and to prevent these adverse effects 
various agents have been developed. Products consisting 
of hyaluronic acid, CMC, oxidized regenerated cellulose, 
extended polytetrafluoroethylene, polysaccharide, fibrin, 
crystalloids, phospholipids and polyethylene glycol have 
been tested for efficacy [1, 2, 4]. Some studies show good 
anti-adhesive results [30–33], others fail to demonstrate 
any clinical improvement and instead severe side effects 
such as edema, ascites, infections, anastomotic leakage, 
abscess, and coagulopathy were observed [34–37].
Seprafilm®, Adept ® and Intergel® are the most popu-
lar products on the market. Seprafilm® has been shown 
to reduce postoperative adhesions after general abdomi-
nal surgery [28, 38]; after its application around a bowel 
anastomosis the risk of anastomotic dehiscence, abscess, 
peritonitis, fistula and inflammatory reactions might be 
increased [28, 37]. In a multicenter randomized study, 
patients requiring a Hartmann procedure for diverticuli-
tis or obstructive bowel disorder were either treated with 
Seprafilm® as an adhesion barrier or were left untreated; 
the results showed that the incidence of adhesions did 
not differ significantly between two treatment groups, 
but the severity of peritoneal adhesion were significantly 
decreased in the Seprafilm® treated patients [39]. The 
authors concluded that long term follow-up studies are 
needed to assess the impact of Seprafilm® on cost-effec-
tiveness in preventing bowel obstruction and infertility. 
Fazio et  al. investigated if the application of Seprafilm® 
reduces the adhesion related small bowel obstruction in 
patients operated for open small bowel, or colorectum 
Table 4 Adhesions
# Missing data: for 3 patients in A-Part Gel, 1 patient in control
## Missing data: for 3 patients in A-Part Gel, 4 patients in control
### Missing data: for 5 patients in A-Part Gel, 8 patients in control
#### Missing data: for 14 patients in A-Part Gel and 15 patients in the control group
Adhesion rates along the scar (mean) (IIT; n = 60) A-Part-Gel (N = 30) Control (N = 30)
Day 14 after surgery# 0.663 0.572
90 % CI [0.538, 0.789] 90 % CI [0.448, 0.695]
Day 28 after surgery## 0.549 0.450
90 % CI [0.428, 0.670] 90 % CI [0.317, 0.548]
3 months after surgery### 0.432 0.253
90 % CI [0.298, 0.565] 90 % CI [0.145, 0.362]
3 months after surgery (video assessment)#### 0.437 0.280
90 % CI [0.246, 0.627] 90 % CI [0.100, 0.460]
Rate of patients experiencing adhesion (IIT; n = 60) A-Part-Gel (N = 30) Control (N = 30)
Day 14 after surgery# 0.852 0.793
90 % CI [0.629, 0.948] 90 % CI [0.632, 0.906]
Day 28 after surgery## 0.889 0.731
90 % CI [0.737, 0.969] 90 % CI [0.553, 0.866]
3 months after surgery### 0.720 0.591
90 % CI [0.538, 0.861] 90 % CI [0.395, 0.767]
3 months after surgery (video assessment)#### 0.686 0.533
90 % CI [0.452, 0.868] 90 % CI [0.300, 0.756]
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resections [40]. After a mean follow-up of 3.5  years the 
frequency of adhesive small bowel obstruction requir-
ing reoperation was significantly lower for Sepra-
film® patients in comparison to the untreated control 
group, whereas the overall bowel obstruction rate was 
unchanged [40].
Another randomized controlled trial evaluated the 
safety and efficacy of Intergel® in colorectal surgery [41]. 
After its use a higher frequency of anastomotic leakage 
dehiscence and wound infection were recorded in con-
trast to an untreated control group. Due to a high rate 
of postoperative complications in the Intergel® treated 
group the study was prematurely terminated [41].
In a randomized, monocenter trial the safety and effec-
tiveness of Adept® was evaluated in comparison to a con-
trol group in reducing the incidence, extent, and severity 
of peritoneal adhesion after surgery for small bowel 
obstruction [42]. Safety of the product has confirmed 
by several authors in regard to anastomotic leakage and 
wound dehiscence [23, 42]. The recurrence rate of small 
bowel obstruction was significantly higher in the control 
group but no statistically significant difference in adhe-
sion severity and the need of surgery for adhesion related 
small bowel obstruction was found [42].
With PVA membranes promising results were obtained 
but these membranes cannot be applied at every surgi-
cal site [17]. Therefore, a gel is considered to be a good 
option as an adhesion prophylaxis. Currently, no prod-
uct is available which shows uniformly safety and effi-
cacy in all surgical conditions. Therefore, none of these 
mentioned agents have become a standard to prevent 
postoperative adhesions and a safe and effective adhesion 
prophylaxis is still missing.
A-Part-Gel® composed of CMC and PVA demon-
strated good results in regard to biocompatibility and 
adhesion to the tissue [8, 9]. Several animal models 
indicated the safety and efficacy of this new barrier gel 
[11–16]. The amount of adhesions was significantly 
decreased in the PVA/CMC hydrogel group compared to 
the untreated control in a rat model [13, 14]. Ditzel et al. 
evaluated A-Part Gel versus Icodextrin 4 % in a rat model 
for the prevention of adhesions. Whereas the application 
of A-Part Gel significantly reduces the amount and the 
density of adhesions no effect was seen after treatment 
with Icodextrin 4  % [14]. These findings are in agree-
ment to Müller et al. who determined the anti-adhesion 
efficacy of A-Part Gel® versus Adept® in a rabbit uterus 
model [15]. To predict the prevalence of adhesion ref-
ormation after adhesiolysis and relaparotomy, abdomi-
nal ultrasound assessment was used in a rabbit sidewall 
model [12]. Here, in contrast to an untreated control 
group a significantly reduction of the extent and quality 
of the abdominal adhesions was observed by the authors 
after the usage of A-Part Gel®. Accuracy of ultrasound 
assessment for adhesions was reported to be 86 %, speci-
ficity was 100 % and sensitivity was 81 %. Also the com-
parison between Icodextrin 4  % and A-Part Gel® as a 
adhesion barrier in a rabbit model showed high effective-
ness of A-Part Gel® in contrast to Icodextrin 4 % [12]. In 
addition, anastomotic leakages and wound healing were 
not negatively influenced after its use [11–14].
Material properties and preclinical results have estab-
lished the promising possibility of A-Part Gel® as a new 
device against postoperative adhesions and therefore, 
this clinical trial was primarily designed for a first assess-
ment of its safety in humans. The primary endpoint of 
this randomized controlled study was the safety of the 
product assessed by the combined endpoint “the fre-
quency of wound healing impairment and postopera-
tive peritonitis within 28 days after surgery”. The rate of 
postoperative peritoneal adhesions judged by ultrasound 
assessment within 3 months and postoperative peritoni-
tis and adverse effects were secondary endpoints [17].
Our data show that A-Part Gel® is safe as an anti-adhesive 
barrier, because its application did not lead to an increase 
of the occurrence of wound healing impairment and/or 
postoperative peritonitis within 28  days after operation. 
In addition, the incidence of anastomotic leakage was low 
and comparable with the control group. Therefore, A-Part 
Gel® treatment can be regarded as safe and not inferior to 
the untreated control. Postoperative adhesions detected by 
non-invasive abdominal ultrasound within 3 months post-
operatively were similar between both treatment groups, 
but due to the small sample size CIs were large and no firm 
statistical conclusions on efficacy could be drawn. Because 
there was a small imbalance regarding the number of bowel 
anastomoses (slightly higher in the control group compared 
to the A-Part Gel group), an adjusted analysis was requested 
by one referee. For the primary safety endpoint wound heal-
ing impairment and/or peritonitis and the secondary safety 
endpoints the number of events was too small for this kind 
of analysis. For the efficacy endpoint adhesion an adjusted 
analysis was performed, which showed similar results as the 
unadjusted analysis.
Limitations of our trial are the monocenter design and 
the fact that it was not designed for an investigation of 
efficacy with sufficient statistical power. Furthermore, the 
non-invasive ultrasound technique was used to deter-
mine adhesion formation, because previous investigation 
using ultrasonography for peritoneal adhesions mapping 
indicated that this method is the standard technique to 
predict abdominal adhesions [20–22]. It is obvious that 
a second look operation which can be potentially per-
formed in gynecologic patients would be more reliable; 
due to ethical aspects this was not an option in the cur-
rent study population.
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In contrast to most preclinical results [9–16] except 
one [43] the data of this study do not support the strong 
adhesion prevention effect. According to preclinical dos-
age studies 1 ml gel per 1 cm incision should be sufficient 
[12–14] but next to the above mentioned study limita-
tions the A-Part Gel® might not have been stayed in 
place because of movement effects. Recently Slieker et al. 
[43] analysed the effect of A-Part Gel on the healing of 
colonic anastomoses using a rat model compared to an 
untreated control group. No significant difference was 
found regarding the incidence of anastomotic leakage 
and no reduction in the amount of adhesions was seen in 
rats treated with A-Part Gel in comparison to controls. 
Weaknesses of this animal study have been described 
by the authors. Pre-study power analysis have been per-
formed for anastomotic leakage not for the prevention 
of adhesions and showed 16 animals per group to be suf-
ficient but mainly based on theoretical supposition [43]. 
Therefore, to define A-Part Gel® as an effective adhesion 
prophylaxis, a larger randomized trial powered on an 
anti-adhesion endpoint with a second look procedure is 
mandatory to draw clinical relevant conclusions.
Conclusion
Our results indicate that A-Part Gel® is safe for the appli-
cation as an adhesion prophylaxis but our data could not 
support the adhesion prevention effects demonstrated in 
different animal studies. This may be due to the limita-
tions of the sample size as well as to application gaps of 
the gel coverage along the abdominal wall incisions.
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